Generic Name and Formulations:
Prazosin HCl 1mg, 2mg, 5mg; caps.
Indications for MINIPRESS:
Give 1st dose at bedtime. 1mg 2–3 times daily. Increase dose slowly. Usual dose: 6–15mg/day in divided doses; max 20–40mg/day. When adding another antihypertensive, reduce dose to 1–2mg 3 times daily and retitrate.
Syncope. Pregnancy (Cat.C). Nursing mothers.
Limit alcohol intake. Hypotension with propranolol, diuretics, other antihypertensives. False (+) pheochromocytoma test.
Syncope (esp. 1st dose), dizziness, headache, drowsiness, weakness, palpitations, GI upset, edema, orthostatic hypotension, dyspnea, vertigo, depression, nervousness, rash, urinary frequency, blurred vision, reddened sclera, epistaxis, dry mouth, nasal congestion; priapism (rare).
Caps 1mg, 2mg—250, 1000
Caps 5mg—250, 500
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML